Search: onr:"swepub:oai:DiVA.org:liu-173378" >
Multicentre testing...
-
Schön, Thomas,1973-Linköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten,Region Östergötland, Infektionskliniken i Östergötland,Department of Infectious Diseases and Clinical Microbiology, Kalmar County Hospital, Kalmar, Sweden
(author)
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
Elsevier,2021
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-173378
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-173378URI
-
https://doi.org/10.1016/j.cmi.2020.10.019DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:146227754URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Finding: ESCMID
-
OBJECTIVES: The first objective of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) subcommittee for antimycobacterial susceptibility testing (AMST), launched in 2016, was to set a reference method for determining the MICs of antituberculous agents, since many protocols are used worldwide and a consensus one is needed for the determination of microbiological breakpoints.METHODS: During 2017 and 2018, MIC determination protocols were evaluated prospectively in a multicentre study within the four AMST laboratories. MIC results were obtained for isoniazid, levofloxacin and amikacin on the reference strain Mycobacterium tuberculosis H37Rv ATCC 27294. Broth microdilution (BMD) in Middlebrook 7H9 and solid medium dilution (SMD) in Middlebrook 7H10 were performed using two inoculum concentrations. MICs were interpreted with regard to visual and 99% inhibition after 7, 14 or 21 days of incubation for BMD and 21 days for SMD.RESULTS: Following the EUCAST reference protocol, intra- and inter-assay agreements were within ±1 MIC dilution for >95% of the observations for the three drugs in both methods. MIC values, presented as MIC mode (range) for BMD and SMD respectively, were: 0.03 (0.015-0.06) mg/L and 0.12 (0.06-0.25) mg/L for isoniazid, 0.25 mg/L (0.25-0.5) and 0.5 mg/L (0.12-0.5) for levofloxacin, and 0.5 mg/L (0.5-1.0) and 0.5 mg/L (0.5-1.0) for amikacin.CONCLUSIONS: Both SMD and BMD were reproducible and eligible as a reference method for MIC determination of the Mycobacterium tuberculosis complex (MTBC). BMD was finally selected as the EUCAST reference method. From now on it will be used to set epidemiological cut-off values and clinical breakpoints of new and old antituberculous agents.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Werngren, JimPublic Health Agency of Sweden, Department of Microbiology, Unit of Laboratory Surveillance of Bacterial Pathogens, 171 82 Solna, Sweden
(author)
-
Machado, DianaUnit of Medical Microbiology of the Instituto de Higiene e Medicina Tropical and Global Health and Tropical Medicine from Universidade NOVA de Lisboa, P-1349-008 Lisboa, Portugal
(author)
-
Borroni, EmanueleEmerging Bacterial Pathogen, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
(author)
-
Wijkander, MariaPublic Health Agency of Sweden, Department of Microbiology, Unit of Laboratory Surveillance of Bacterial Pathogens, 171 82 Solna, Sweden
(author)
-
Lina, GerardCIRI, Centre International de Recherche en Infectiologie, Université Lyon 1, Ecole Normale Supérieure de Lyon, and Centre National de Référence des Staphylocoques, Institut des Agent Infectieux, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
(author)
-
Mouton, JohanDepartment of Medical Microbiology and Infectious Diseases, Research and Development Unit, Erasmus Medical Centre, Rotterdam, the Netherlands
(author)
-
Matuschek, ErikaDepartment of Clinical Microbiology, Central Hospital, and EUCAST Development Laboratory, Växjö, Sweden
(author)
-
Kahlmeter, GunnarDepartment of Clinical Microbiology, Central Hospital, and EUCAST Development Laboratory, Växjö, Sweden
(author)
-
Giske, ChristianKarolinska Institutet,Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
(author)
-
Santin, MiguelDepartment of Infectious Diseases, Bellvitge University Hospital-IDIBELL, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
(author)
-
Cirillo, Daniela MariaEmerging Bacterial Pathogen, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
(author)
-
Viveiros, MiguelUnit of Medical Microbiology of the Instituto de Higiene e Medicina Tropical and Global Health and Tropical Medicine from Universidade NOVA de Lisboa, P-1349-008 Lisboa, Portugal
(author)
-
Cambau, EmmanuelleAPHP-GHU Nord, Mycobactériologie Spécialisée et de Référence, Laboratoire Associé du Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), and Université de Paris, INSERM, IAME UMR1137, F-75006 Paris, France
(author)
-
Linköpings universitetAvdelningen för inflammation och infektion
(creator_code:org_t)
Related titles
-
In:Clinical Microbiology and Infection: Elsevier27:2, s. 288.e1-288.e41198-743X1469-0691
Internet link
Find in a library
To the university's database
- By the author/editor
-
Schön, Thomas, 1 ...
-
Werngren, Jim
-
Machado, Diana
-
Borroni, Emanuel ...
-
Wijkander, Maria
-
Lina, Gerard
-
show more...
-
Mouton, Johan
-
Matuschek, Erika
-
Kahlmeter, Gunna ...
-
Giske, Christian
-
Santin, Miguel
-
Cirillo, Daniela ...
-
Viveiros, Miguel
-
Cambau, Emmanuel ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Infectious Medic ...
- Articles in the publication
-
Clinical Microbi ...
- By the university
-
Linköping University
-
Karolinska Institutet